Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector
Reexamination Certificate
2003-01-03
2009-12-01
Parkin, Jeffrey S. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
C424S580000
Reexamination Certificate
active
07625565
ABSTRACT:
This invention relates to the area of immunology and virology, and specifically relates to compositions obtainable from mammalian thymus cells which are useful as diagnostics, vaccines, and therapeutics for human immunodeficiency virus (HIV) infection and related diseases such as acquired immunodeficiency syndrome (AIDS) and AIDS-related complex (ARC). The diagnostic, vaccination, and therapeutic methods, and devices, using these compositions are also disclosed.
REFERENCES:
patent: 4415553 (1983-11-01), Zhabilov et al.
patent: 5783557 (1998-07-01), Burstein et al.
patent: A 0 149 468 (1985-07-01), None
patent: A 0 392 315 (1990-10-01), None
patent: WO A 89 05455 (1989-06-01), None
patent: WO A 93 21943 (1993-11-01), None
Antonsen, K. P., et al., 1992, Immunoadsorption.strategies for antigen elution and production of reusable adsorbents, Biotech. 8(3):168-178.
Jack, G. W., 1994, Immunoaffinity chromatography, Mol. Biotech. 1(1):59-86.
Sanz-Nebot, V., et al., 1999, Fractionation and characterization of a crude peptide mixture from the synthesis of eledoisin by liquid chromatography-electrospray ionization mass spectrometry, J. Chromat. A, 846(1-2):25-38.
Lajmi, A. R., et al., 2000, Short, hydrophobic, alanine-based proteins based on the basic region/leucine zipper protein motif: Overcoming inclusion body formation and protein aggregation during overexpression, purification, and renaturation, Prot. Exp. Purif. 18(3):394-403.
Scopes, R.K., 2000, Overview of protein purification and characterization, Curr. Prot. Prot. Sci., John Wiley & Sons, Inc., 1.1.1- 1.1.6.
Navratilova, I., et al., 2005, Solublization, stabilization, and purification of chemokine receptors using biosensor technology, Anal. Biochem. 339(2):271-281.
Harvima, R. J., et al., 1988, Hydrolysis of histones by proteinases, Biochem. J. 250(3):859-864.
Hayashi, H., and K. Iwai, 1976, Calf thymus histone H2A, J. Biochem. 80(4):681-692 (abstract only provided).
Schnittman et al., “Human Immunodeficiency Virus and Acquired Immunodeficiency Syndrome: An Update,” Adv. Int. Med., vol. 39, pp. 305-355 (1994).
Dorner et al., “Minimum Safety Requirements for Preclinical Testing,” Dev. Biol. Stand., vol. 81, pp. 245-252 (1993).
Saag, M., “Clinical Spectrum of Human Immunodeficiency Virus Diseases,” AIDS: Biology, Diagnosis, Treatment and Prevention, fourth edition, Lippincott-Raven Publ., pp. 203-213 (1997).
Graham et al., “Candidate AIDS Vaccines,” New England Journal of Medicine, vol. 333, pp. 1331-1339, (1995).
Haynes, B., “Scientific and Social Issues of Human Immunodeficiency Virus Vaccine Development,” Science, vol. 260, pp. 1279-1286 (1993).
Gait et al., “Progress in Anti-HIV Structure-Based Drug Design,” Tibtech, vol. 13, pp. 430-438.
Anderson, et al., “Effect of Dose and Immunization Schedule on Immune Response of Baboons to Recombinant Glycoprotein 120 of HIV-1,” J. Infect. Diseases, 160:960 (1989).
Jacobson et al., “Surrogate Markers for Survival in Patients with AIDS and AIDS related complex treated with Zidovudine,” BMJ, 302:73 (1991).
Stein, et al., “CD4+Lymphocyte Cell Enumeration for Prediction of Clinical Course of Human Immunodeficiency Virus Disease: A Review,” J. Infect. Diseases 165:352 (1992).
Yarchoan et al., “Clinical Aspects of Infection with AIDS Retrovirus: Acute HIV Infection, Persistant Generalized Lymphadenopathy, and AIDS-Related Complex,” in AIDS: etiology, diagnosis, treatment and prevention, eds. DeVita et al., pp. 107-120 (1988).
Fasman, G., “CRC Handbook of Biochemistry and Molecular Biology,” CRC Press Inc., Boca Rotan, Florida, pp. 294-300 (1989).
Stollar, David et al., “Separation of Anti-histone Antibodies from Noninnune Hitone-precipitating Serum Proteins, Predominantly a2-Macroglobulin,” Arch. Biochem. & Biophys., vol. 190(2) pp. 398-404 (1978).
Stein, D. et al., Immune-Based Therapeutics: Scientific Rationale and the Promising Approaches to the Treatment of the Human Immunodeficiency Virus-Infected Individual.
Saag, Michael, “Use of Virologic Markers in Clinical Practice,” Journal of Acquired Immune Deficiency Syndrome and Human Retrovirology, vol. 15, pp. S3-S13 (1997).
Shohat et al., Immune Modulation of a T-Suppressor Cell Lymphoma by Thymic Humoral Factor, a Thymic Hormone, Biochemistry, vol. 27, pp. 4066-4071 (1988).
Burstein et al., “Thymic Humoral Factor λ 2: Purification and Amino Acid Sequence of an Immunoregulatory Peptide from Calf Thymus,” American Chemical Society, vol. 27(11) pp. 4066-4071 (1988).
Saag, Michael, “Candidate Antiretroviral Agents for Use in Postexposure Prophylaxis,” American Journal of Medicine, Vol. 102(5B) Supplement, pp. 25-30 (1997).
Kisselev et al., “Human Immunodeficiency Virus Type 1 Proteinase Is Rapidly and Efficiently Inactivated in Human Plasma by Macroglobulin,” vol. 375, pp. 711-714 (1994).
Athauda et al., “Entrapment and Inhibition of Human Immunodeficiency Virus Proteinase by α2-Macroglobulin and Structural Changes in the Inhibitor,” J. Biochem, vol. 113, pp. 742-746 (1993).
Trainin, Nathan, Prospects of AIDS Therapy by Thymic Humoral Factor, a Thymic Hormone, Nat. lmmun Cell Growth Regul, pp. 155-159 (1990).
Rager-Zisman et al., 'Thymic Humoral Factor, THF-λ2, Enhances Immunotherapy of Murine Cytomegalovirus (MCMV) Infection by Both CD4+CD8+Immune T Cells, Immunology Letters, pp. 23-31 (1994).
Pecht et al., “Potentiation of Myeloid Colony-Formation in Bone Marrow of Intact and Neonatally Thymectomized Mice by the Thymic Hormone THF-λ2,” Experimental Hematology, vol. 21, pp. 277-282 (1993).
Zhabilov Harry H.
Zhabilov Harry P.
Zhabilov, legal representative Jordanka
Berliner & Associates
Parkin Jeffrey S.
Viral Genetics, Inc.
LandOfFree
Antiviral compositions comprising lysine-rich histone... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antiviral compositions comprising lysine-rich histone..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antiviral compositions comprising lysine-rich histone... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4147457